Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

LIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today ... Convention in Philadelphia, PA. , The presentation took place on Tuesday, June ... plans for the development of APX3330 for the treatment of pancreatic cancer. A ...
(Date:6/30/2015)... - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that ... approved the resolutions relating to: (i) a private ... at a price of $2.67 per unit (the ... one common share and 0.075358 common share purchase ... and (ii) the amendment to Resverlogix,s articles to ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome ... on mechanics of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, ... patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections ...
(Date:6/30/2015)... , June 30, 2015  The University ... in Biosciences (CCE/Bio) and UC San Diego Extension ... to be held Aug.  12 – 14, 2015, ... This three-day workshop provides an intense exposure to ... biotechnology, and is well-suited to biologists, process engineers ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2
... ... Biodiesel Refinery, HOUSTON, March 4 ... has satisfied the conditions precedent,and completed its first funding of $10.6 ... one of the world,s leading,financial services providers for alternative energy companies. ...
... Forget About Storage and Focus on Business, NEW ... provider, announces the launch of ExaStore Clustered NAS 2008,designed ... full range of,applications and environments., "Organizations have seen ... considerable burden," says Dr. Arnon Gat, Exanet,President & CEO. ...
... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... virus (HCV) infection, today announced that it will release ... 2008 on March 11,2008 at 7:00 a.m. EDT and ... results at 11:30 a.m. EDT on the same day., ...
Cached Biology Technology:Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility 2Exanet Announces ExaStore 2008 Clustered NAS System 2Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results 2
(Date:6/23/2015)... June 23, 2015  Crossmatch™, a leading ... today announced enhanced functionality of its DigitalPersona ... The enhancements build on the native flexibility ... Altus platform and provide expanded mobile credential ... In today,s environment of increasing cyber-attacks and ...
(Date:6/17/2015)... HILDEN, Germany , June 17, 2015 /PRNewswire/ ... Prime Standard: QIA) today launched new Investigator ® STR ... in the United States . The new ... multiple key genomic markers (short tandem repeats or STRs) for ... to evaluate the quality of DNA in each sample, a ...
(Date:6/16/2015)... , June 16, 2015  With the increasing number ... remains a top concern. The recent compromise of ... need for strong authentication within government agencies. ... biometric one-time password (OTP) authenticator, has been submitted for ... 140-2 Level 3 validation for tamper proofing. ...
Breaking Biology News(10 mins):Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ...
... ages will celebrate the science and technology of the ... the inaugural Atlanta Science Festival, March 22-29, 2014. With ... schools and universities, the festival will host more than ... across the city. Learn more at http://atlantasciencefestival.org . ...
... Cargo in Efficient and Sustainable Global Logistics Operations) is ... in the efficiency of intermodal loading systems and the ... comprises 29 European organisations with experience in the logistics ... budget totalling 17,000,000 and a duration of three and ...
Cached Biology News:New gut microbiome research to explore red meat -- colorectal cancer pathway 2First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2
... versatile Zymo-Spin I-96 Plate can be used ... for the large-scale (i.e., 96-well) purification of ... construction and unique silica-based matrix make it ... DNA or RNA in = 10 l ...
...
...
...
Biology Products: